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Abstract
Objective—To describe fetal and neonatal mortality due to congenital anomalies in Colombia.
Methods—We analyzed all fetal and neonatal deaths due to a congenital anomaly registered with 
the Colombian vital statistics system during 1999–2008.
Results—The registry included 213,293 fetal deaths and 7,216,727 live births. Of the live births, 
77,738 (1.08%) resulted in neonatal deaths. Congenital anomalies were responsible for 7321 fetal 
deaths (3.4% of all fetal deaths) and 15,040 neonatal deaths (19.3% of all neonatal deaths). The 
fetal mortality rate due to congenital anomalies was 9.9 per 10,000 live births and fetal deaths; the 
neonatal mortality rate due to congenital anomalies was 20.8 per 10,000 live births. Mortality rates 
due to congenital anomalies remained relatively stable during the study period. The most frequent 
fatal congenital anomalies were congenital heart defects (32.0%), central nervous system 
anomalies (15.8%), and chromosomal anomalies (8.0%). Risk factors for fetal and neonatal death 
included: male or undetermined sex, living in villages or rural areas, mother's age >35 years, low 
and very low birthweight, and <28 weeks gestation at birth.
Conclusions—Congenital anomalies are an important cause of fetal and neonatal deaths in 
Colombia, but many of the anomalies may be preventable or treatable.
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Introduction
Congenital anomalies, also called birth defects or congenital disorders, are conditions 
leading to high infant mortality and disability [1]. It is estimated that worldwide each year 
330,000 newborns die during the first 28 days of life due to congenital anomalies [1]. 
Whereas neonatal mortality is decreasing as labor care and the prevention of infectious 
diseases has improved, the proportion of deaths due to premature birth or birth defects has 
been increasing [2]. As a result, congenital anomalies must be addressed in order to finish 
the work of the World Health Organization's 4th Millennium Development Goal related to 
reducing child mortality and the related Sustainable Development Goals [3].
The Pan American Health Organization (PAHO) has reported that in Colombia 
approximately 20% of all deaths in children younger than five years of age are related to 
congenital anomalies [4]. Furthermore, among children under one year of age, congenital 
anomalies are the second leading cause of death in Colombia [4]. This and other reports (e.g. 
[5,6]), however, have important limitations, which may include little information on time 
trends, geographic distributions, or major risk determinants of congenital anomaly-related 
mortality. Furthermore, data are typically only available on under-five or infant mortality, 
rather than neonatal, or perinatal mortality (i.e. including fetal deaths) [4].
To address these research gaps in Colombia, we carried out a study of death certificates to 
describe trends and characteristics of fetal and neonatal mortality due to congenital 
anomalies during 1999–2008 according to type of congenital anomaly, as well as 
geographical, socioeconomic, and obstetric determinants.
Methods
Data source
We reviewed all fetal and neonatal deaths registered at the Colombian vital statistics system 
of the National Administrative Department of Statistics (known as DANE) during the period 
1999–2008. Fetal death was defined as death prior to birth of a fetus weighing at least 500 
grams (g). Neonatal death was defined as death of a liveborn baby occurring within 28 days 
after birth. Deaths due to congenital anomalies were classified according to the tenth 
revision of the International Classification of Diseases (ICD-10), chapter XVII Q000-Q999 
for congenital malformations, deformations, and chromosomal abnormalities. During these 
years some changes were made in how the DANE vital statistics system collected and 
categorized certain variables; therefore, we standardized categories for maternal age, 
gestational age, and birthweight in order to ensure comparability over time. DANE is 
responsible for cleaning the database to avoid duplicate information.
Statistical analysis
The analysis was done using Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA), 
SPSS 18® (SPSS, Chicago, IL) and Epi-Info© version 3.5.3 (CDC, Atlanta, GA). 
Descriptive statistics (numbers, percentages, and rates) are presented. We defined the fetal 
mortality rate as number of fetal deaths per 10,000 live births and fetal deaths, and we 
defined the neonatal mortality rate as the number of neonatal deaths per 10,000 live births. 
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We calculated these rates for both overall fetal and neonatal mortality, and also for fetal and 
neonatal mortality due to congenital anomalies. We calculated these mortality rates by year 
and computed the proportions of fetal and neonatal deaths due to congenital anomalies.
In addition, using information available on the death certificate, we calculated descriptive 
statistics according to the following characteristics: type of congenital anomaly, type of 
residence (urban, villages, or rural), maternal age, infant sex, birth weight, gestational week, 
maternal education level, number of living children, health insurance, and civil marriage 
status. However, we were unable to calculate mortality rates for the last four variables 
because the live births database did not record information on them. For selected mortality 
rates, we compared variable characteristics using the Mantel–Haenszel chi square test.
Ethical considerations
This study followed the good clinical practice guidelines and the guidelines of the Helsinki 
Declaration. The publically available vital statistics database did not contain any identifiers, 
there was no contact with any of the affected families, and no samples were taken. Thus, 
according to national regulations (resolution 008430 of 1993), our study was considered to 
be without risks for the participants and exempt from human subjects review.
Results
During 1999–2008 a total of 213,293 fetal deaths and 7,216,727 live births were registered 
(Table 1). Of the live births, 77,738 (1.08%) resulted in neonatal deaths. Congenital 
anomalies were responsible for 7321 fetal deaths (3.4% of all fetal deaths) and 15,040 
neonatal deaths (19.3% of all neonatal deaths) (Table 1). The fetal mortality rate due to 
congenital anomalies was 9.9 per 10,000 live births and fetal deaths, while the neonatal 
mortality rate due to congenital anomalies was 20.8 per 10,000 live births (Table 1).
Over time, the fetal mortality rate due to congenital anomalies did not exhibit a clear trend 
(Figure 1), although rates were lower than the mean in 2004 and 2008 and higher than the 
mean in 2007. This lack of clear trend was in contrast to overall fetal mortality rates, which 
increased substantially from 217.4 per 10,000 live births and fetal deaths in 1999–422.8 per 
10,000 live births and fetal deaths in 2008. The combination of stable fetal deaths due to 
congenital anomalies and rising numbers of overall fetal deaths resulted in a decrease in the 
percentage of fetal deaths due to congenital anomalies from 4.0% in 1999 to 1.8% in 2008.
Similarly, the neonatal mortality rate due to congenital anomalies did not exhibit a clear 
trend and in fact appeared nearly constant during 1999–2008, with the exception of 1999, 
where the rate was about 10% lower than the mean (Figure 1). This lack of trend was also in 
contrast to the overall neonatal mortality rates, which decreased from 125.1 per 10,000 live 
births in 1999 to 91.9 per 10,000 live births in 2008 (Table 1). The combination of stable 
neonatal deaths due to congenital anomalies and decreasing numbers of fetal deaths resulted 
in an increase in the percentage of neonatal deaths due to congenital anomalies from 14.5% 
in 1999 to 22.8% in 2008.
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The distribution of mortality due to congenital anomalies within each year was rather 
homogeneous, although a higher rate was usually observed during the months of September 
and October (data not shown).
Among combined fetal and neonatal deaths due to congenital anomalies, the most frequent 
category (Table 2) was congenital heart defects (32.0%), followed by central nervous system 
anomalies (15.8%) and chromosomal anomalies (8.0%). However, for neonatal deaths only, 
a much larger proportion was due to congenital heart defects (45.0%) than to central nervous 
system anomalies (14.1%) or chromosomal anomalies (2.2%). In contrast, for fetal deaths 
only, a larger proportion was due to central nervous system anomalies (18.9%) and 
chromosomal anomalies (20.0%) than to congenital heart defects (6.1%). The collection of 
“other” congenital anomalies also contributed to a substantial proportion of fetal deaths 
(46.6%) and neonatal deaths (16.7%) due to congenital anomalies.
The most frequent congenital heart defect reported among fetal and neonatal deaths was 
unspecified congenital heart disease (65%) followed by hypoplastic left heart syndrome 
(3.2%), ventricular septal defect (2.8%), and aortic coarctation (2.4%) (Table 2). Neural tube 
defects (anencephaly, spina bifida and encephalo-cele) accounted for 50% of the central 
nervous system anomalies among fetal and neonatal deaths (including 39% due to 
anencephaly alone), followed by hydrocephalus (24%) and brain hypoplasia (6%). The 
majority of the chromosomal abnormalities among fetal and neonatal deaths were 
“unspecified” chromosomal abnormalities (77%), followed by Edwards syndrome (9%), 
Patau syndrome (6%), and Down syndrome (6%).
For variables whose rates could be computed, the characteristics with higher fetal and 
neonatal mortality rates due to congenital anomalies included: male or undetermined sex 
(versus female sex, p<.01), living in villages or rural areas (versus urban area, p<.001), 
mother's age >35 years (versus ≤35 years, p<.001), low and very low birth-weight (versus 
normal birth-weight, p<.001), and ≤28 weeks gestation at birth (versus >28 weeks, p<.001) 
(Table 3). Fetal and neonatal mortality rates due to congenital anomalies were also elevated 
when there was missing information on these characteristics (Table 3).
Discussion
We found that congenital anomalies are important contributors to fetal and neonatal 
mortality in Colombia. Over a 10-year period, congenital anomalies caused more than 
22,000 fetal and neonatal deaths, including over 3% of fetal deaths and nearly 20% of 
neonatal deaths. It is difficult to compare these proportions with other countries in the region 
because limited data have been published on fetal and neonatal mortality due to congenital 
anomalies. We were only able to identify one comparable study in the region, where it was 
reported that in Costa Rica congenital anomalies contributed to 4% of fetal deaths [7].
Although we did not observe clear time trends in neonatal mortality due to congenital 
anomalies, given the inherent limitations of death certificate data it is still possible that some 
modest underlying trends were present. As overall neonatal mortality decreased, neonatal 
mortality due to congenital anomalies remained relatively stable, meaning that congenital 
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anomalies are contributing to higher proportions of neonatal mortality each year. Similar 
trends have been observed worldwide [2]. Thus, to reduce overall neonatal mortality, new 
approaches may be needed in Colombia for decreasing the occurrence of congenital 
anomalies and the occurrence of death among neonates with congenital anomalies.
Fetal mortality rates due to congenital anomalies were more volatile over time. For three 
years (2004, 2007, and 2008), rates were substantially different (−31.6%, 60.2%, and 
−24.4%, respectively) from the 10-year average (9.9%). All-cause fetal mortality was also 
more volatile over time, but experienced an overall increase that did not clearly correspond 
to increases and decreases in fetal mortality due to congenital anomalies. The volatility is 
likely due in part to smaller denominators for fetal deaths compared to neonatal deaths, 
leading to uncertainty about whether there were any long-term trends in fetal mortality due 
to congenital anomalies. It is possible that fetal mortality is rising because of better 
ascertainment, rather than because of increased incidence, but whatever the explanation, the 
data do not suggest that congenital anomalies are contributing substantially to that rise.
Although many types of congenital anomalies resulted in fetal and neonatal deaths, a large 
proportion of deaths were attributable to congenital anomalies that are potentially treatable 
or preventable. A recent study conducted in Colombia revealed that adequate treatment 
could improve outcomes in more than 80% of newborns with non-lethal anomalies [6]. In 
our study, nearly half (45.0%) of neonatal deaths were caused by congenital heart defects, 
many of which might be treatable [8].
The next biggest specific contributor to fetal and neonatal deaths was central nervous system 
anomalies, of which half were neural tube defects. Many neural tube defects can be 
prevented if women consume adequate folic acid prior to and during the peri-conceptional 
period, either through vitamin supplements or fortified food [9,10]. In fact, neural tube 
defects occurrence can be reduced to less than seven cases per 10,000 live births if women 
have adequate blood folate levels [11]. Several studies have shown that the occurrence of 
neural tube defects has decreased by 20–70% following implementation of folic acid food 
fortification policies [12–15]. Colombia passed folic acid food fortification legislation in 
1996 [16], but our data were collected after fortification was implemented, so we cannot 
determine whether deaths due to neural tube defects decreased after implementation. 
Therefore, it would be important to collect other data to assess whether rates of neural tube 
defects have reached optimal levels achievable through food fortification [17] across all 
population groups [18].
Another important finding was that mortality rates due to congenital anomalies increased 
substantially as one moves away from urban areas. In particular, rates were more than three 
times higher in villages and six times higher in rural areas compared to urban areas. In 
Chile, infant mortality due to congenital anomalies was also elevated in rural areas [19]. 
Similar urban/rural disparities were found in Down syndrome birth rates in Australia, where 
the authors suggested that differences could be caused by inequities in access to prenatal 
screening and care [20]. Contributors to higher mortality rates in rural Colombia may 
include lack of access to care and treatment to prevent death, and higher underlying rates of 
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congenital anomalies due to risk factors such as insufficient folic acid intake because 
fortified staple foods may not be available or affordable.
Consistent with previous studies [19,21], maternal age was another important predictor of 
mortality due to congenital anomalies. Rates were approximately 70% higher when mothers 
were ≥35 years of age compared to younger mothers. This may be because older mothers are 
more likely to have babies with congenital anomalies such as Down syndrome. Other studies 
[7,22,23] have found higher rates of some congenital anomalies among women aged 35–40 
[23], but mortality was not assessed. Older maternal age has also been associated with fetal 
mortality in general [24], which is what we found in our data, but it is nclear how much that 
association can explain higher rates of fetal mortality due to congenital anomalies among 
older women. Male sex was also associated with slightly higher mortality due to congenital 
anomalies, which is consistent with previous findings of male excess for a number of 
congenital anomalies [25].
Unsurprisingly, mortality rates due to congenital anomalies were higher with very low 
birthweights and very early gestational ages. These birth outcomes are likely to be the result 
rather than the cause of congenital anomalies.
Of note, mortality rates due to congenital anomalies were much higher when accompanying 
information was missing, such as residence, mother's age, or birth-weight, suggesting that 
death certificates may be less rigorously filled out when a congenital anomaly is present, or 
that the mother or other family members may be less likely to provide this information when 
a congenital anomaly is present.
The problem of assigning cause of death has been a common difficulty in studies 
investigating congenital anomalies, especially among the fetal deaths where a high 
percentage of deaths are defined as “unspecified reasons” [26]. Our study also found a high 
number of cases without a specifically defined cause of death (data not shown). Therefore, 
there is a need to implement strategies within the healthcare system to improve the 
registration of causes of death, thus leading to a better understanding of the burden caused 
by various congenital anomalies [27]. In addition, better death registration in Colombia 
would improve the evaluation of preventive interventions, such as folic acid food 
fortification, that target congenital anomalies [15].
This study had several strengths. The study included 10 years of national data, allowing for a 
country-wide assessment of trends over an extended time period. Furthermore, we reported 
not only neonatal mortality rates, but also fetal death rates. Very few studies have looked at 
the burden of congenital anomalies from the perspective of perinatal mortality. This study 
also provided evidence of the need for better reporting of causes of death and identified 
subpopulations with higher rates of perinatal mortality due to congenital anomalies.
This study had several limitations. Examining death certificates only captures a small 
portion of the burden caused by congenital anomalies. Many children with congenital 
anomalies survive but face serious challenges of disability, intensive medical care, and 
stigma [28]. Also, as previously mentioned, there was a large proportion of reported deaths 
without a specified cause. In addition, vital records surveillance underestimates the 
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occurrence of birth defects overall in comparison with active surveillance [29]. Thus, the 
prevalence of perinatal mortality due to congenital anomalies is likely to be underestimated. 
Another limitation from our study was that all variables had missing values, making it more 
difficult to assess risk factors for mortality due to congenital anomalies. Furthermore, in 
some cases there was a discrepancy between direct cause of death and underlying cause of 
death, indicating shortcomings in the official mortality register and highlighting the urgent 
need to train medical doctors on the identification of congenital anomalies and the correct 
reporting of cause of death to the vital statistics officials [30].
Furthermore, the database did not contain information on congenital anomalies that resulted 
in elective termination of pregnancy, which is another reason that the true impact of 
congenital anomalies in this population was underestimated.
In conclusion, we did not observe any clear increasing or decreasing trends in fetal or 
neonatal mortality rates due to congenital anomalies between 1999 and 2008; the rates 
remained relatively stable over this time period. These surveillance data are useful for 
identifying regional, demographic, and socioeconomic risk factors affecting fetal and 
neonatal mortality in Colombia. These data also point to an opportunity for intervention, 
since they show that many deaths due to congenital anomalies may be preventable or 
treatable. These interventions can be targeted to address those subpopulations that have the 
biggest risk factors for mortality due to congenital anomalies. Finally, there is an urgent need 
to implement population-based surveillance to monitor all occurrence of congenital 
anomalies rather than only fatal congenital anomalies, and to improve early identification 
and referral to services for newborns that survive.
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Figure 1. 
Fetal and neonatal mortality trends by year of death, Colombia, 1999–2008.
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